Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| DMAE (Dimethylaminoethanol) | Piracetam | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 150-400 mg/day (as DMAE bitartrate, typically 37% DMAE) | 1200-4800 mg/day divided into 2-3 doses |
| Timing | Morning. With or without food. | With or without food; split doses morning and afternoon to maintain plasma levels |
| Cycle Duration | Ongoing; no strict cycling required | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment |
| Evidence Level | animal_plus_anecdotal | moderate_human |
Structural analog of choline that crosses the BBB more readily than choline itself. Paradoxically increases choline availability not by serving as a direct precursor to acetylcholine, but by inhibiting choline metabolism in peripheral tissues, thereby increasing circulating choline available for brain uptake. Also acts as a free radical scavenger and membrane stabilizer. Reduces lipofuscin accumulation in neuronal cells, an age pigment associated with cellular aging.
150-400 mg/day (as DMAE bitartrate, typically 37% DMAE)
Morning. With or without food.
Ongoing; no strict cycling required
Positive allosteric modulator of AMPA receptors, binding at a unique site along the dimer interface to reduce desensitization and deactivation. Inhibits N-type calcium channels at clinically relevant CNS concentrations. Enhances membrane fluidity of neuronal phospholipids and modulates neurotransmission across cholinergic and glutamatergic systems.
1200-4800 mg/day divided into 2-3 doses
With or without food; split doses morning and afternoon to maintain plasma levels
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →